Ability of myeloma cells to secrete macrophage inflammatory protein (MIP)-1alpha and MIP-1beta correlates with lytic bone lesions in patients with multiple myeloma.
about
Tgf-Beta inhibition restores terminal osteoblast differentiation to suppress myeloma growthNovel therapeutic targets in myeloma bone disease.Multiple myeloma/hypercalcemia.CCR1 blockade reduces tumor burden and osteolysis in vivo in a mouse model of myeloma bone diseaseBone lesions and macrophage inflammatory protein-1 alpha (MIP-1a) in human multiple myeloma.Evolutionary Dynamics of Tumor-Stroma Interactions in Multiple Myeloma.Significance of macrophage inflammatory protein-1 alpha (MIP-1alpha) in multiple myeloma.Role of the microenvironment in multiple myeloma bone disease.Chemokines in multiple myelomaImmunotherapy of multiple myeloma: the start of a long and tortuous journey.Treatment strategies for bone disease.Maytansinoid immunoconjugate IMGN901 is cytotoxic in a three-dimensional culture model of multiple myeloma.Mechanisms of multiple myeloma bone disease.Adenosine regulates bone metabolism via A1, A2A, and A2B receptors in bone marrow cells from normal humans and patients with multiple myeloma.Cancer phenotype as the outcome of an evolutionary game between normal and malignant cellsThe inflammatory chemokine CCL5 and cancer progressionCCR1 as a target for multiple myeloma.Soluble molecules and bone metabolism in multiple myeloma: a review.The ecology of cancer from an evolutionary game theory perspective.Mechanisms of osteolytic and osteoblastic skeletal lesions.The macrophage inflammatory proteins MIP1α (CCL3) and MIP2α (CXCL2) in implant-associated osteomyelitis: linking inflammation to bone degradation.Adipose, Bone, and Myeloma: Contributions from the Microenvironment.Osteolytic lesions, cytogenetic features and bone marrow levels of cytokines and chemokines in multiple myeloma patients: Role of chemokine (C-C motif) ligand 20.Pathogenesis of myeloma bone disease.p38 mitogen-activated protein kinase inhibitor LY2228820 enhances bortezomib-induced cytotoxicity and inhibits osteoclastogenesis in multiple myeloma; therapeutic implications.Myeloma cell expression of 10 candidate genes for osteolytic bone disease. Only overexpression of DKK1 correlates with clinical bone involvement at diagnosis.Pro-inflammatory State in Monoclonal Gammopathy of Undetermined Significance and in Multiple Myeloma Is Characterized by Low Sialylation of Pathogen-Specific and Other Monoclonal Immunoglobulins.Targeting myeloma-osteoclast interaction with Vγ9Vδ2 T cells.Bone destruction in multiple myeloma.Increased serum levels of MIP-1alpha correlate with bone disease and angiogenic cytokines in patients with multiple myeloma.Brain-derived neurotrophic factor is a potential osteoclast stimulating factor in multiple myeloma.
P2860
Q28473419-01D96B9F-59DC-4964-AC41-8FE15ADD4427Q34025065-B0F5A270-FB4D-4DB6-AF0D-B1DE8AC2F03FQ35901084-11B47B44-F65A-4026-9810-081DD4E51EAEQ36177928-3B2DE212-8A3E-43AC-BE82-CFE014191185Q36194693-0DE9DF7B-6B62-488B-AA2F-F619A6700F32Q36234799-5709CDE4-E3DE-458C-8C0A-D61581F29DC4Q36303451-40BFABFE-4673-4C6C-9EBB-0952072A025FQ36512521-FABCD8B0-C69B-47FE-BB55-38050E33B253Q36596949-B72EDDB4-C678-4051-BDB6-29F3324F25D4Q36689152-83AA00B7-C9FA-45D2-BCBC-6A1212D868F4Q36902828-310C2A2D-6F31-447B-A193-869D73583D10Q37019223-E5A3A5EE-E7A0-4B00-A6F4-66281EA0BACAQ37056408-BE15ADDF-FDFB-4AF9-A8E5-4F4055910689Q37118787-0AA63E44-8F86-4D14-9C2D-0E9F44F0C4A8Q37400506-8DFAFAF5-0FAC-420B-974A-B870A13126C9Q37541911-08331939-B8B4-43CE-8309-1A9EDD5FA303Q37879210-65496C97-BD39-44E5-A7F4-7C5583A06B1CQ37998401-BAD4843F-90A4-4ACC-A66C-35FB75DDA33AQ38237394-2356DFAB-69EE-4451-85E5-318C5A8C8306Q38625793-10E0802E-8BE3-461C-8DD3-4D10061E18E4Q38724068-76606169-8181-4AF0-B0AB-3DC9CA0C1EB9Q38876521-A94F8A78-9158-4F51-A8CB-F78DD464B168Q40485837-607EAAA4-3A66-4C67-8628-C874882D3A9CQ46224909-FB360B81-AA0C-4D08-87EC-2A0D6A48A039Q46657407-E62F87F2-119F-43DB-A8FD-48779D3F9816Q46898670-B7FE4194-CC85-4525-A49B-4AF4A26B6B48Q47132349-C8007A12-EFBA-49BD-9B3E-7D3241FDF2E1Q53238656-02AC4E10-ACC6-42B1-B700-1A220BB76B25Q53612379-1053BD1F-E019-42AE-A8D7-F577D933D9B9Q54535110-5F1179E7-E5C8-4975-88B4-09ADAB966F72Q54604723-F954042A-B16E-413F-ADF7-986CD447C22E
P2860
Ability of myeloma cells to secrete macrophage inflammatory protein (MIP)-1alpha and MIP-1beta correlates with lytic bone lesions in patients with multiple myeloma.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Ability of myeloma cells to se ...... atients with multiple myeloma.
@en
Ability of myeloma cells to secrete macrophage inflammatory protein
@nl
type
label
Ability of myeloma cells to se ...... atients with multiple myeloma.
@en
Ability of myeloma cells to secrete macrophage inflammatory protein
@nl
prefLabel
Ability of myeloma cells to se ...... atients with multiple myeloma.
@en
Ability of myeloma cells to secrete macrophage inflammatory protein
@nl
P2093
P2860
P1476
Ability of myeloma cells to se ...... atients with multiple myeloma.
@en
P2093
Daisuke Inoue
Hironobu Shibata
Masahiro Abe
Shuji Ozaki
Takashi Oshima
Toshihiro Hashimoto
Toshio Matsumoto
P2860
P356
10.1111/J.1365-2141.2004.04864.X
P407
P577
2004-04-01T00:00:00Z